AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$DRTS

Levy Raphi sold $161K of DRTS

Levy Raphi (Chief Financial Officer) sold 15,000 shares of Alpha Tau Medical Ltd. (DRTS) at $10.76 ($0.16M total) on 2026-06-03.

Original reporting
SEC EDGAR · Levy Raphi
Published Jun 4, 2026, 6:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DRTS
Neutral
medium confidence
Mentioned
$DRTS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRTSNeutralLow
01

Why it matters

This provides a fresh, timestamped datapoint on insider behavior but does not introduce new operational or financial information about DRTS.

02

Market read

Traders may monitor for follow-through selling pressure, but the filing alone is unlikely to reset valuation without additional company catalysts.

03

What to watch

No 10b5-1 plan is indicated, but the article also lacks context on total insider holdings, prior sales cadence, or whether other insiders/large holders acted similarly.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today; sale executed on 2026-06-03

Background

The article is an SEC Form 4 insider transaction disclosure for Alpha Tau Medical Ltd. (DRTS).

Company-level read

Ticker impact

$DRTSNeutralMedium confidence
Context

Alpha Tau Medical CFO Levy Raphi sold 15,000 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a new fundamental driver.

Evidence & confidence

The filing provides a concrete datapoint (sale size, price, post-transaction holdings) but no accompanying company-specific news (earnings, trial, deal, guidance).

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide read-across provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale was open-market and not explicitly tied to distress; insiders often sell for diversification or planned liquidity needs.

Key entities

  • issuer
    Alpha Tau Medical Ltd.

    Company whose CFO insider sale is disclosed on SEC Form 4.

  • insider
    Levy Raphi

    Chief Financial Officer who sold 15,000 shares on 2026-06-03.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min